AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00758589
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, 50 mg twice daily
Trial: NCT00758589
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, 400 mg twice daily
Trial: NCT00758589
Drug: AZD1981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet, 1000 mg twice daily
Trial: NCT00758589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03551548
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo once daily on top of standard therapy, started 14 ± 4 days before cardiac surgery and continued during 30 days after surgery.
Trial: NCT01825941
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01229579
Drug: Zinc Sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
Trial: NCT01547091
Drug: Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
Trial: NCT03289169
Drug: MEDITOXIN®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20U of Meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
Trial: NCT01035346
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
Trial: NCT01035346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of a placebo
Trial: NCT00206882
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02981524
Drug: CY
RxNorm normalized name: CYT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CY is administered intravenously at 200 mg/m2
Trial: NCT00984581
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
Trial: NCT04485689
Drug: Placebo - alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours
Trial: NCT04485689
Drug: Placebo - ice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5x7 cm2 patch applied on the dorsal area of the hand and left in place for 24 hours. Ice will be applied on top of the patch 1.5 hrs post patch application and left in place for 1 hr.
Trial: NCT01300351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
Trial: NCT02677844
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT03277261
Drug: Oral Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT03277261
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an IV infusion.
Trial: NCT01252290
Drug: Lovaza™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 capsules daily for 6 months
Trial: NCT02949388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
Trial: NCT01123473
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01123473
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00722917
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
Trial: NCT00940784
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, aspirin (81-100 mg qd) plus hydroxyurea
Trial: NCT00875173
Drug: Placebo (for Selenium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with similar flavor, smell and colour.
Trial: NCT04334213
Drug: D745, D150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04334213
Drug: CKD-501, D745, D150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT04033094
Drug: Comparator Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
Trial: NCT00286221
Drug: PCA fentanyl
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted
Trial: NCT00286221
Drug: PRN fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
Trial: NCT02616770
Drug: S1226 (4%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
Trial: NCT02616770
Drug: S1226(8%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
Trial: NCT02616770
Drug: S1226(12%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
Trial: NCT02771626
Drug: CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutaminase inhibitor
Trial: NCT01848470
Drug: CG400549 640mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
Trial: NCT01848470
Drug: CG400549 320 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
Trial: NCT01848470
Drug: CG400549 640 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
Trial: NCT01848470
Drug: CG400549 960 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
Trial: NCT01848470
Drug: Placebo 640mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
Trial: NCT01848470
Drug: Placebo 320mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
Trial: NCT01848470
Drug: placebo 960 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
Trial: NCT01848470
Drug: Placebo 640mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
Trial: NCT02115360
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
Trial: NCT01507285
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial single dose followed by subsequent multiple s.c. (under the skin) doses
Trial: NCT04145570
Drug: Tarceva®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarceva® 150 mg
Trial: NCT00002816
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002816
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02179814
Drug: AMPT/ Demser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
Trial: NCT02179814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo at the second, third and fourth medication intake time point
Trial: NCT00002816
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03469921
Drug: administered therapeutic regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered therapeutic regimens
Trial: NCT00747409
Drug: human regular insulin and NPH insulin (Actrapid, Protaphne)
RxNorm normalized name: insulin, regular, human Injectable Solution [Human Actrapid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: basal-bolus therapy with human regular and NPH insulin
Trial: NCT04518163
Drug: placebo to TA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 110 ml saline by slow infusion before skin incision
Trial: NCT00213096
Drug: Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00064402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID
Trial: NCT03132025
Drug: Apatinib and Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer
Trial: NCT03132025
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer
Trial: NCT00351273
Drug: Doxycycline and Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
Trial: NCT00351273
Drug: Azithromycin and Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
Trial: NCT00351273
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose
Trial: NCT00810940
Drug: AbelaDrug200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP \< 20 mmHg, then IV 100 ml same schedule for 24 hours
Trial: NCT04073160
Drug: Intravesicular Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive intravesicular therapy, if clinically indicated during cycles 5 and beyond of durvalumab administration. Intravesicular therapy will consist of BCG, gemcitabine, mitomycin or a similar drug, depending on institutional standards and treating provider's discretion.
Trial: NCT03417661
Drug: HEXI-PREP By Clinell Wipes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile single sachet wipe containing 3ml solution.
Trial: NCT01378429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00316420
Drug: Capecitabine (Xeloda)
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
Trial: NCT02574741
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% of the subjects will be randomized to placebo (inactive study medication).
Trial: NCT03417661
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline (0.9% w/v) wipe, containing 3ml of solution.
Trial: NCT01723579
Drug: Estradiol (E2)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily release of 1.5 mg
Trial: NCT01987479
Drug: Non-Biologic DMARDs
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
Trial: NCT01987479
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered per investigator's discretion.
Trial: NCT04510051
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04197817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo,Subcutaneous or intravenous injection of a single dose of placebo, dose cohort according to ascending dose design
Trial: NCT04055038
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy
Trial: NCT04335786
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the time of randomization each participant will start with study treatment and continue up to 14 days, or up to reaching the primary endpoint, or up to hospital discharge, or up to any of the pre-defined stopping criteria.
Trial: NCT02903030
Drug: Maltose (placebo)
RxNorm normalized name: Maltose
DrugBank: Maltose (DB03323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltose with a trace amount of silicon dioxide
Trial: NCT02903030
Drug: Visbiome Extra Strength
RxNorm normalized name: Visbiome Extra Strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
Trial: NCT02080169
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl is used as analgesic drug in order to obtain the VAS \<3.
Trial: NCT03323671
Drug: preemptive mefenamic acid
RxNorm normalized name: Meclofenamic Acid
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: preemptive analgesia before menstrual pain
Trial: NCT03323671
Drug: mefenamic acid
RxNorm normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: mefenamic acid given only during menstruation
Trial: NCT00431119
Drug: Azathioprine or Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04208087
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be intravesically instilled.
Trial: NCT03055390
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2ml of saline intravenous
Trial: NCT00658515
Drug: Evidence-based medical care for Acute Coronary Syndrome
RxNorm normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00658515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po daily
Trial: NCT01805388
Drug: Experimental: Regeneration Treatment Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
Trial: NCT00402493
Drug: ibuprofen, latanoprost, brimonidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
Trial: NCT00402493
Drug: Ibuprofen, brimonidine, latanoprost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
Trial: NCT00402493
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 200mg
Trial: NCT01058941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo LA and placebo oil capsules for 18 months
Trial: NCT03712111
Drug: Norepinephrine 6 mcg
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of norepinephrine 6 mcg will be administered for management of maternal hypotension.
Trial: NCT03712111
Drug: Norepinephrine 10 mcg
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An intravenous bolus of norepinephrine 10 mcg will be administered for management of maternal hypotension.
Trial: NCT03712111
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic norepinephrine infusion will be started after subarachnoid block
Trial: NCT02098889
Drug: hyoscine-N-butyl bromide(HBB)
RxNorm normalized name: n-butyl acrylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
Trial: NCT01123824
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: matching tablets~Route of administration: oral
Trial: NCT00280566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
Trial: NCT03065556
Drug: Vehicle Solution
RxNorm normalized name: compounding vehicle solution sugar free no. 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical solution containing no active drug
Trial: NCT01238965
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01238965
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01237782
Drug: Denture soaking solution
RxNorm normalized name: ALCOHOL,DENATURED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
Trial: NCT00849108
Drug: BMS747158
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosages at rest and at stress were not to exceed a total of 14 mCi.~Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.~Cohort 2: Patients to recieve IV bolus injections of BMS747158:~For the Pharmacologic (Adenosine) Stress:~* Doses at rest were to range between 2.9 and 3.4 mCi.~* Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.~For the Exercise Stress:~* Doses at rest were to range between 1.7 and 2.0 mCi.~* Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi.
Trial: NCT00825721
Drug: C-KAD Ophthalmic Solution
RxNorm normalized name: urea c-13 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 drops applied daily for 360 days
Trial: NCT02757079
Drug: NPC-15
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
Trial: NCT01631916
Drug: corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
Trial: NCT03480009
Drug: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
RxNorm normalized name: Avicel PH101 (Microcrystalline Cellulose NF) for Compounding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT02326441
Drug: KX2-361
FDA approved: no
EMA approved: no
PMDA approved: no